All AbMole products are for research use only, cannot be used for human consumption.
INCB086550 selectively inhibited PD-L1 with IC50 of 3.1 nM, 4.9 nM and 1.9 nM for human, rhesus monkey and rat pD-L1, respectively. INCB086550 could not inhibit the binding of PD-L2 to PD-1 at 10 μM. INCB086550 significantly inhibits the PD-1/PD-L1 signaling axis by binding to PD-L1 protein, leading to PD-L1 dimerization and internalization, and has good tumor suppressive effect in a variety of mouse tumor models.
In vitro studies showed that INCB086550 could selectively inhibit PD-L1: the IC50 of INCB086550 on human, rhesus monkey and rat PD-L1 were 3.1 nM, 4.9 nM and 1.9 nM, respectively. INCB086550 could not inhibit the binding of PD-L2 to PD-1 at 10 μM.
INCB086550 could significantly inhibit the binding of PD-1 to human PD-L1 on Chinese hamster ovary (CHO) cells with an IC50 of 13 nM, and the inhibitory effect was more than 90% when INCB086550 concentration exceeded 160 nM.
Flow cytometry and confocal confocal results showed that INCB086550 and PD-L1 monoclonal antibodies (Atezolizumab and Durvalumab) competed to bind to the same site. INCB086550 rapidly induces the dimerization and internalization of PD-L1, and causes its transfer to the nucleus, reducing the level of PD-L1 on the cell surface.
After INCB086550 blocked PD-L1, the ability of PD-1 to recruit protein tyrosine phosphatase (SHP) was decreased, thus enhancing the signal intensity of activated T nuclear factor (NFAT) and promoting the secretion of IFN-γ by immune cells in human peripheral blood.
In vivo antitumor efficacy: On the transplanted tumor model of mouse colon cancer cell line MC38 (expressing human PD-L1), twice daily INCB086550 at 2 mg/kg, 20 mg/kg and 200 mg/kg reduced tumor volume by 32%, 66% and 69%, respectively, on day 16.
Human CD34 positive hematopoietic stem cells were injected into NSG severely combined with immunodeficient mice, and the tumor bearing experiment of breast cancer (MDA-MB-231) was conducted to construct the humanized mouse tumor model. Tumor-bearing mice were given INCB086550 twice daily at 20 mg/kg, 60 mg/kg and 200 mg/kg, and tumor volume decreased by 55%, 54% and 61%, respectively, on day 21. No observable side effects were observed.
| Molecular Weight | 693.79 |
| Formula | C41H39N7O4 |
| CAS Number | 2230911-59-6 |
| Solubility (25°C) | Water ≥ 60 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related PD-1/PD-L1 Products |
|---|
| Avelumab (MSB0010718C)
Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). Avelumab recognizes murine PD-L1 |
| Panaxadiol
Panaxadiol exists in ginseng root and has neuroprotective and anti-tumor functions. Panaxadiol inhibits the expression of programmed cell death ligand-1 (PD-L1) and tumor proliferation. |
| Fraxinellone
Fraxinellone was isolated from the root bark of the brassica family Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor that inhibits HIF-1α synthesis without affecting HIF-1α degradation. Fraxinellone has potential for cancer immunity by targeting PD-L1. |
| BMS202
Bms-202 is an effective non-peptide PD-1/PD-L complex inhibitor with IC50 of 18 nM and KD of 8 μM. Bms-202 directly binds to PD-L1 and blocks the human PD-1/PD-L interaction. Bms-202 has antitumor activity. |
| Sulfamethoxypyridazine
Sulfamethoxypyridazine is a long-acting sulfonamide for treatment of Dermatitis herpetiformis. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
